Company news

Cansino Biologics, Inc. Class A (SSE:688185) news

Cansino Biologics, Inc. Class A news releases on 6ix. Latest, Sep 17, 2026: "Cansino Biologics Inc."Announcement on Granting Certain Reserved Restricted…

Cansino Biologics, Inc. Class A (SSE:688185) news

Press releases & updates

"Cansino Biologics Inc."Announcement on Granting Certain Reserved Restricted Shares to Participants under the 2025 A-Share Restricted Share Incentive Plan

"Cansino Biologics Inc."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Biological Products and CXO Industry

"Cansino Biologics Inc."Semi-annual Report for 2026

"Cansino Biologics Inc."Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Performance Briefing

"Cansino Biologics Inc."Announcement on Abnormal Fluctuations in Stock Trading

"Cansino Biologics Inc."Announcement on Obtaining Drug Registration Certificate for Adsorbed Tetanus Vaccine

"Cansino Biologics Inc."Announcement on Voluntary Disclosure of Acceptance of the Drug Registration Application for Adsorbed Tetanus, Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine (For Persons Aged 6 and Above)

CanSino Biologics : CanSinoBIO's Menhycia® Application Accepted by China's NMPA for Expanded Use in Population Aged 3 Months to 17 Years

CanSino Biologics : CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Expanding Global Reach

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Voluntary Disclosure of Initiating Phase I/II Clinical Trial and Completing 1st Subject Enrollment for the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)

Announcement on Changing Location of 2025 Annual General Meeting

Announcement on Voluntary Disclosure of Official Inclusion of the Adsorbed Acellular Pertussis (5-Component), Diphtheria and Tetanus Combined Vaccine (for People Aged 6 and Above) into the Priority Review List

Science and Technology for People's Well-being - Achievement of Enterprises on SSE STAR Market and Its Empowerment of People's Livelihood Conference

Announcement on Amending the "Articles of Association" and Its Attachments and Formulating the "Remuneration Management System for Directors and Senior Management Members"

Announcement on Obtaining the Drug Registration Certificate for the Adsorbed Inactivated (Three-component) Diphtheria-Tetanus-Pertussis Vaccine for Infants and Young Children

Announcement on Requesting the General Meeting to Authorize the Board of Directors to Issue Shares to Specific Objects by Summary Procedure

Announcement on Voluntary Disclosure of Obtaining PIC/S GMP Certification

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Obtaining the Supplementary Application Approval Notice for the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Carrier)

CanSinoBIO at WGS 2026: Accelerating Global Access to Innovative Vaccines

Announcement on Earnings Preannouncement for 2025

Announcement on Obtaining Notice of Approval for Drug Clinical Trial for 24-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197, TT)

Announcement on Notifying the Creditors of Offsetting Losses with Capital Reserve

Announcement on Implementation of Cancellation of Repurchased A-shares

Announcement on Voluntary Disclosure of the Initiation of Phase 1 Clinical Trial and Completion of 1st Subject Enrollment for Inhalable Tuberculosis Vaccine (Type 5 Adenovirus Vector) in Indonesia

Announcement on Adding Extraordinary Proposal to the 2nd Extraordinary General Meeting in 2025

Announcement on Adjusting Matters Related to the 2025 A-share Restricted Stock Incentive Plan

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025

Board of Supervisors' Remarks on Publicity of and Verification Opinions on List of Incentive Objects Initially Granted under 2025 A-share Restricted Stock Incentive Plan

-- Announcement on Resolutions of the 9th Meeting of the 3rd Board of Supervisors

-- Announcement on Attending 2025 Online Collective Reception Day for Investors of Listed Companies in Tianjin Jurisdiction and Semi-annual Report Performance Briefing

-- Announcement on Using Temporarily Idle Raised Funds for Cash Management

-- Announcement on Obtaining Notice of Approval for Drug Clinical Trial for Recombinant Trivalent Poliomyelitis Vaccine (Sf-RVN Cell)

Announcement on the Obtainment of Drug Registration Certificate for 13-valent Pneumococcal Polysaccharide Vaccine (CRM197/Tetanus Toxoid)

Announcement on Resolution of the 2024 Annual General Meeting

Voluntary Disclosure on the Approval of Clinical Trial for Inhaled Tuberculosis Vaccine (Adenovirus Type 5 Vector) in Indonesia

Notice on Convening the 2024 Annual General Meeting

Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing

Announcement on Renewing Engagement of Accounting Firm

Announcement on Preliminary Earnings Estimate for 2024

Announcement on Obtaining the Approval Notice for Drug Clinical Trials of Adsorbed Acellular Pertussis (Components), Tetanus, Diphtheria, Haemophilus Influenzae Type b (Conjugate), and Meningococcal Group ACYW135 (Conjugate) Combined Vaccine

Announcement on Voluntary Disclosure of Formal Inclusion of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children in Priority Review Varieties

Announcement on Voluntary Disclosure of Acceptance of Drug Registration Application for Adsorbed Tetanus Vaccine

Announcement on Annual Earnings Preannouncement for 2024

Announcement on the Voluntary Disclosure of the Obtaining of the Registration Certificate in Indonesia for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)

Announcement on Voluntary Disclosure of Initiation of Phase II/III Clinical Trial for Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed (for Population Aged 6 and Above) and Completion of First Subject Enrollment in Phase II Clinical Trial

Announcement of the Acceptance of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children

Indicative Announcement on the Termination of Partial Shareholders' Concerted Action Relationship and Changes in Equity